← Back to Analyst Consensus 
MGX Buy
Metagenomi Therapeutics, Inc.
Current Price —
Implied Upside —
Analysts 9
30-Day Momentum
▲ 0 upgrades / ▼ 0 downgrades / 0 reiterations from 0 firms
Next Earnings
Nov 18, 2026 (23 days)
Rating Timeline
| Date ▼ | Firm | Action | From → To Rating | Price Target | Firm Rating |
|---|---|---|---|---|---|
| Aug 11, 2026 | Wells Fargo | maintain | Overweight → Overweight | — | 54% |
| Jul 7, 2026 | Chardan Capital | maintain | Buy → Buy | — | 47% |
| May 12, 2026 | Wells Fargo | maintain | Overweight → Overweight | — | 54% |
| Aug 19, 2025 | HC Wainwright & Co. | reiterate | Buy → Buy | $7 | 44% |
| Aug 15, 2025 | Chardan Capital | maintain | Buy → Buy | $11 | 47% |
| Aug 14, 2025 | Wells Fargo | maintain | Overweight → Overweight | $12 | 54% |
| May 15, 2025 | Chardan Capital | maintain | Buy → Buy | $12 | 47% |
| May 14, 2025 | Wells Fargo | maintain | Overweight → Overweight | $16 | 54% |
| Apr 3, 2025 | HC Wainwright & Co. | maintain | Buy → Buy | $7 | 44% |
| Mar 18, 2025 | Wells Fargo | maintain | Overweight → Overweight | $20 | 54% |
| Dec 10, 2024 | HC Wainwright & Co. | maintain | Buy → Buy | $14 | 44% |
| Nov 21, 2024 | HC Wainwright & Co. | reiterate | Buy → Buy | $7 | 44% |
| Nov 20, 2024 | Chardan Capital | maintain | Buy → Buy | $15 | 47% |
| Oct 15, 2024 | HC Wainwright & Co. | reiterate | Buy → Buy | $7 | 44% |
| Sep 6, 2024 | HC Wainwright & Co. | reiterate | Buy → Buy | $7 | 44% |
| Sep 5, 2024 | Chardan Capital | maintain | Buy → Buy | $15 | 47% |
| Aug 21, 2024 | HC Wainwright & Co. | maintain | Buy → Buy | $7 | 44% |
| Aug 19, 2024 | Chardan Capital | maintain | Buy → Buy | $15 | 47% |
| Aug 15, 2024 | BMO Capital | maintain | Outperform → Outperform | $17 | 53% |
| Jul 15, 2024 | HC Wainwright & Co. | reiterate | Buy → Buy | $10 | 44% |
| May 15, 2024 | HC Wainwright & Co. | reiterate | Buy → Buy | $10 | 44% |
| May 7, 2024 | HC Wainwright & Co. | initiate | — → Buy | $10 | 44% |
| May 2, 2024 | JP Morgan | downgrade | Overweight → Neutral | $6 | 54% |
| Mar 28, 2024 | Chardan Capital | maintain | Buy → Buy | $21 | 47% |
| Mar 5, 2024 | TD Cowen | initiate | — → Outperform | $0 | 54% |
| Mar 5, 2024 | Wells Fargo | initiate | — → Overweight | $25 | 54% |
| Mar 5, 2024 | JP Morgan | initiate | — → Overweight | $16 | 54% |
| Mar 5, 2024 | Jefferies | initiate | — → Buy | $23 | 52% |
| Mar 5, 2024 | BMO Capital | initiate | — → Outperform | $22 | 53% |
| Mar 5, 2024 | Chardan Capital | initiate | — → Buy | $21 | 47% |
Price Target Trend
Apr 3, 2026 Oct 26, 2026
EPS Estimates
+1q —
0q —
0y —
+1y —
Cross-Platform Signals
No cross-platform signals in the last 90 days